TRACON Pharmaceuticals

Receive alerts
Market Cap:
$14.45 m
1.70 USD
52 weeks high
52 weeks low

In brief

TRACON (NASDAQ:TCON) is a U.S. biotech with a product development platform that offers corporate partners CRO-independent clinical development and U.S. commercialization expertise.  TRACON has in-licensed N. American rights to a subcutaneous PD-L1 antibody for sarcoma (12/19) expected to initiate a US registrational trial in 2020, a prostate cancer asset from J&J (2016) expected to have a P2 read-out in 2020, a CD73 antibody from I-Mab (2018) in a P1 trial and rights to multiple  bi-specific antibodies, one or more of which are expected to be IND ready in 2020. An antibody out-licensed to Santen is expected to have P2 data in 2020.

Deep dive We explore the investor case for growth companies


The San Diego company utilizes a capital-efficient product development platform to develop its clinical-stage pipeline of cancer therapies

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Biotech companies to dominate at Proactive One2One Virtual Investor Forum on June 23

TRACON Pharmaceuticals, Helix BioPharma, Tetra Bio-Pharma and MediPharm Labs are among the standouts presenting at the investor-focused event

on 23/6/20